Loading...
Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma
Opinion statement Treatment for relapsed/refractory (R/R) Hodgkin and non-Hodgkin lymphoma remains challenging. The introduction of rituximab to B cell non-Hodgkin lymphoma (B-NHL) treatment significantly improved patients’ response rate and survival; however, approximately one third of patients wit...
Saved in:
| Published in: | Curr Treat Options Oncol |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2016
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5578701/ https://ncbi.nlm.nih.gov/pubmed/27193488 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11864-016-0401-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|